Adaptive Biotechnologies Corporation (NASDAQ:ADPT) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. • Adaptive Biotechnologies stock is trending lower.
Why are ADPT shares declining?
Adaptive Separation Plan Could Sharpen Focus On MRD Business William Blair, in an investor note on Tuesday, agreed with the assessment and said the move the firm believes could simplify the company's investment story and create greater strategic flexibility for its Minimal Residual Disease (MRD) franchise.
Analyst Andrew Brackmann said investors will likely seek more clarity on the future of the Immune Medicine segment, with management expected to identify its preferred path by the end of the year.
"Regardless, we like this move as it simplifies the thesis and adds flexibility, particularly for the MRD franchise," Brackmann wrote.
